Literature DB >> 34820734

The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI.

Elena Di Sabatino1, Lorenzo Gaetani1, Silvia Sperandei1, Andrea Fiacca2, Giorgio Guercini2, Lucilla Parnetti1, Massimiliano Di Filippo3.   

Abstract

BACKGROUND: Measures to define treatment response, such as no evidence of disease activity (NEDA), are routinely used in multiple sclerosis (MS) clinical practice. Although spinal cord involvement is a frequent feature of MS, its magnetic resonance imaging (MRI) monitoring is not routinely performed.
OBJECTIVE: To assess the impact of spinal cord MRI in the definition of NEDA in a cohort of people with MS (pwMS) with available spinal cord imaging performed as for routine monitoring.
METHODS: We included 115 pwMS undergoing treatment with first-line disease-modifying therapies (DMTs) and retrospectively analyzed the presence of NEDA in the whole cohort, either considering or not spinal cord imaging.
RESULTS: When considering only clinical and brain MRI measures, 97 out of 115 pwMS (84.3%) satisfied the criteria for NEDA. In the same cohort, the number of pwMS with NEDA significantly decreased to 88 (76.5%) (p < 0.01) when considering also spinal cord imaging.
CONCLUSION: These findings suggest that, in routine clinical practice, spinal cord MRI monitoring in pwMS under first-line DMTs leads to a slight but significant change in the proportion of subjects classified as clinically and radiologically stable according to the NEDA definition.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  Disease activity; Magnetic resonance imaging; Monitoring; Multiple sclerosis; NEDA; No evidence of disease activity; Spinal cord

Mesh:

Year:  2021        PMID: 34820734     DOI: 10.1007/s00415-021-10901-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  29 in total

Review 1.  Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review.

Authors:  Annette Langer-Gould; Rita A Popat; Stella M Huang; Kristin Cobb; Paulo Fontoura; Michael K Gould; Lorene M Nelson
Journal:  Arch Neurol       Date:  2006-12

Review 2.  Spinal cord MRI in multiple sclerosis--diagnostic, prognostic and clinical value.

Authors:  Hugh Kearney; David H Miller; Olga Ciccarelli
Journal:  Nat Rev Neurol       Date:  2015-05-26       Impact factor: 42.937

Review 3.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process.

Authors:  Àlex Rovira; Mike P Wattjes; Mar Tintoré; Carmen Tur; Tarek A Yousry; Maria P Sormani; Nicola De Stefano; Massimo Filippi; Cristina Auger; Maria A Rocca; Frederik Barkhof; Franz Fazekas; Ludwig Kappos; Chris Polman; David Miller; Xavier Montalban
Journal:  Nat Rev Neurol       Date:  2015-07-07       Impact factor: 42.937

4.  Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor.

Authors:  Georgina Arrambide; Alex Rovira; Jaume Sastre-Garriga; Carmen Tur; Joaquín Castilló; Jordi Río; Angela Vidal-Jordana; Ingrid Galán; Breogán Rodríguez-Acevedo; Luciana Midaglia; Carlos Nos; Patricia Mulero; Maria Jesús Arévalo; Manuel Comabella; Elena Huerga; Cristina Auger; Xavier Montalban; Mar Tintore
Journal:  Mult Scler       Date:  2017-03-16       Impact factor: 6.312

Review 5.  Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge.

Authors:  Claudio Gasperini; Luca Prosperini; Mar Tintoré; Maria Pia Sormani; Massimo Filippi; Jordi Rio; Jacqueline Palace; Maria A Rocca; Olga Ciccarelli; Frederik Barkhof; Jaume Sastre-Garriga; Hugo Vrenken; Jette L Frederiksen; Tarek A Yousry; Christian Enzinger; Alex Rovira; Ludwig Kappos; Carlo Pozzilli; Xavier Montalban; Nicola De Stefano
Journal:  Neurology       Date:  2018-12-26       Impact factor: 9.910

Review 6.  Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis.

Authors:  Dalia Rotstein; Xavier Montalban
Journal:  Nat Rev Neurol       Date:  2019-05       Impact factor: 42.937

Review 7.  Brain health: time matters in multiple sclerosis.

Authors:  Gavin Giovannoni; Helmut Butzkueven; Suhayl Dhib-Jalbut; Jeremy Hobart; Gisela Kobelt; George Pepper; Maria Pia Sormani; Christoph Thalheim; Anthony Traboulsee; Timothy Vollmer
Journal:  Mult Scler Relat Disord       Date:  2016-07-07       Impact factor: 4.339

8.  Cervical cord lesion load is associated with disability independently from atrophy in MS.

Authors:  Hugh Kearney; Daniel R Altmann; Rebecca S Samson; Marios C Yiannakas; Claudia A M Wheeler-Kingshott; Olga Ciccarelli; David H Miller
Journal:  Neurology       Date:  2014-12-24       Impact factor: 9.910

Review 9.  Defining and scoring response to IFN-β in multiple sclerosis.

Authors:  Maria Pia Sormani; Nicola De Stefano
Journal:  Nat Rev Neurol       Date:  2013-07-30       Impact factor: 42.937

Review 10.  "No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.

Authors:  Gavin Giovannoni; Davorka Tomic; Jeremy R Bright; Eva Havrdová
Journal:  Mult Scler       Date:  2017-04-06       Impact factor: 6.312

View more
  1 in total

Review 1.  Predictive MRI Biomarkers in MS-A Critical Review.

Authors:  Vlad Eugen Tiu; Iulian Enache; Cristina Aura Panea; Cristina Tiu; Bogdan Ovidiu Popescu
Journal:  Medicina (Kaunas)       Date:  2022-03-03       Impact factor: 2.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.